Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer

A case report

Juan Wei, MMa,∗, XiaoFang Dong, MBb, FangMing Du, MBb, Sheng Tang, MMb, HangPing Wei, MMb

Abstract

Rationale: Pancreatic cancer is common in people older than 40 years, and the incidence peaks at the age of 70 years and older. Chemoradiotherapy has been generally considered a high-risk procedure in elderly patients with local recurrent pancreatic cancer. Gamma knife stereotactic radiosurgery has the advantage in protecting the surrounding tissues, and providing short-term effects. It has been successfully used in patients with brain metastases. The efficacy of GKRS in other malignancies has barely been studied. S-1 is one of the key drug against metastatic and local advanced pancreatic cancer. The combination of GKRS and S-1 in local recurrent pancreatic cancer has hardly been reported.

Patient concerns: We present a rare case of a 76-year-old man with pancreatic cancer. He complained of recurrent abdominal pain and chronic pain in the right shoulder for more than 3 years.

Diagnoses: After several examinations, the diagnosis was carcinoma of the pancreas.

Interventions: A resection of the pancreatic neoplasm was performed on June 21, 2011; he did not receive adjuvant chemotherapy. In April 2014, postoperative recurrence was confirmed in the head of the pancreas. The patient received gamma knife stereotactic radiosurgery (GKRS) combined with S-1 treatment.

Outcomes: The patient showed complete response after 2 months. He has achieved an overall survival of 76 months with a very good performance status.

Lessons: GKRS applied to other malignancies has rarely been reported. S-1 is the key drug for adjuvant chemotherapy in resected pancreatic cancer. There are a few studies on this combination in local recurrent pancreatic cancer. GKRS combined with S-1 seems to be a good option in improving efficacy and prolonging life in elderly patients with locally recurrent pancreatic cancer.

Abbreviations: 5-FU = 5-fluorouracil, CA19–9 = carbohydrate antigen 19–9, CR = complete response, CT = computed tomography, GKRS = gamma knife stereotactic radiosurgery.

Keywords: elderly man, gamma knife stereotactic radiosurgery, recurrent pancreatic cancer

1. Introduction

Pancreatic carcinoma is one of the most common malignancies of the digestive system. It most frequently appears in elderly patients, with most patients being diagnosed in the range of 70 to 79 years.1,2 The majority of patients with pancreatic cancer initially present with locally advanced and metastatic disease, and a fewer than 20% have resectable tumors.3 The curative effect and reliability of gamma knife stereotactic radiosurgery (GKRS) have been confirmed in the treatment of brain metastases,4 but its efficacy in other malignancies has barely been reported. The efficacy and safety of S-1 monotherapy against metastatic pancreatic cancer have been established in clinical practice.5 The combination of GKRS and S-1 in local recurrent pancreatic cancer has hardly been studied. We present a rare case of a 79-year-old man with recurrent pancreatic cancer who was treated with GKRS combined with S-1 regimen and showed a good response. The patient has achieved long-term survival of 76 months because of multidisciplinary treatment.

2. Case report

A 76-year-old man was admitted to the hospital in June 2011. He complained of recurrent abdominal pain, accompanied by chronic pain in the right shoulder for more than 3 years. His past medical history was unremarkable. Physical examination did not indicate any abnormalities. An abdominal computed tomography (CT) scan revealed the presence of a hypovascular mass from the neck to the tail of the pancreas with direct invasion of the splenic artery. Resection of the pancreatic neoplasm was performed on June 21 2011. The pathological diagnosis was invasive ductal adenocarcinoma. The postoperative course was uneventful and he did not receive adjuvant chemotherapy. He was in good condition and there was no recurrence detected by...
follow-up periodic imaging or serum tumor markers. The serum tumor marker carbohydrate antigen 19–9 (CA19–9) levels were elevated to 132.3 U/mL (normal limit: 37 U/mL) in April 2014, and contrast-enhanced CT showed a 10 × 8-mm low-attenuating tumor in the head of the pancreas (Fig. 1). Further, positron-emission tomography-CT revealed an abnormal accumulation at the site. Thus, postoperative recurrence was confirmed. A 1-month course of chemotherapy was performed with single-agent S-1 regimen received orally twice a day at a dose calculated according to the body surface area (< 1.25 m², 40 mg/d; ≥ 1.25 to < 1.5 m², 50 mg/d; ≥ 1.5 m², 60 mg/d). He received 120 mg/day on days 1 through 14 of a 21-day cycle. Concurrent GKSRS to the recurrent pancreatic lesion was performed for local control. It was delivered at 5 Gy per fraction every other day, with a total dose of 30 Gy. He received one cycle of chemotherapy with S-1 in March 2014. He felt fatigue and S-1 treatment was discontinued. His CA19–9 serum concentration decreased to 43.4 U/mL in June 2014. Follow-up CT 2 months later showed the lesion had completely disappeared (Fig. 2). The patient showed a complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). He has been disease-free in subsequent follow up with CT since that time and has achieved an overall survival of 76 months with a very good performance status (Karnofsky 90%).

2.1. Ethics approval and consent to participate
This study was approved by the Ethics Committee of Dongyang People’s Hospital. Written informed consent was obtained from the patient for publication of this clinical case.

3. Discussion
Early diagnosis of pancreatic cancer is difficult and the prognosis is very poor, with a median survival of only 4 to 6 months and a 5-year survival rate of approximately 5%. The incidence of pancreatic cancer continues to rise. It is estimated that pancreatic cancer will be the second leading cause of cancer-related death in 2030.\(^6\) Pancreatic cancer is common in people older than 40 years, and the incidence peaks at the age of 70 years and older.\(^1\) The choice of treatment for patients at this age should consider performance status, comorbidity and tolerance to therapy. At present, there is still a lack of clinical guidelines for advanced pancreatic cancer for elderly patients. Some studies indicate that for resectable pancreatic carcinoma, pancreatic resection can be conducted for the elderly with acceptable mortality rates and long-term survival.\(^7\)–\(^10\) Most patients can only tolerate monotherapy caused by a variety of medical conditions. Combined chemotherapy with multiple drugs easily leads to serious complications such as severe liver and kidney function damage, bone marrow suppression, important viscera function failure, refractory infection, bleeding, and even death.

S-1 is a newly developed oral 5-fluorouracil (5-FU) prodrug with demonstrated activity against several cancer types, which consists of tegafur/gimeracil/oteracil in a molar ratio of 1.0:0.4:1.0.\(^11\) S-1 is the key drug in adjuvant chemotherapy for resected pancreatic cancer. Gemcitabine monotherapy is the standard adjuvant chemotherapy for advanced pancreatic cancer. S-1 seems to be more effective compared with gemcitabine as the adjuvant chemotherapy in metastatic pancreatic cancer patients.\(^12\) S-1, an oral fluoropyrimidine derivative, is convenient to take and well tolerated. Therefore, it is easily accepted by elderly outpatients. First-line treatment with S-1 may be a reasonable therapeutic option for elderly patients with pancreatic cancer.\(^13\)

The emergence of GKSRS increases the radiation tumor dose and decreases the normal radiation tissue dose. It also plays a role in protecting the surrounding tissues, relieving symptoms and providing short-term effects, and is well tolerated. GKSRS has been successfully used in the salvage setting for brain metastases in patients for whom whole brain irradiation has failed.\(^14\) However, the efficacy of GKSRS in other malignancies has barely
been studied. This is especially true of patients with pancreatic
cancer who have lower body function. It can be regarded as an
effective treatment method for elderly patients with inoperable
local recurrence of pancreatic cancer.

In this case, S-1 regimen was our best option because our
patient could not tolerate aggressive chemotherapy. We chose to
add concurrent GKSRS over a short treatment period for local
control, which was well tolerated. He had achieved CR after 2
months. 5-FU-based chemoradiotherapy for selected elderly
patients with locally advanced pancreatic carcinoma leads to a
better survival compared with younger patients.15 With careful
patient selection, GKSRS combined with S-1 can be an
appropriate treatment option for elderly patients with local
recurrent pancreatic cancer.

4. Conclusion

We reported the rare case of an elderly man with recurrent
pancreatic cancer who was treated with GKSRS combined with S-
1, which had excellent treatment effect. He is now 82 years old,
and has a very good performance status approximately 76
months after the initiation of treatment.

Acknowledgements

The authors would like to acknowledge and extend our heartfelt
gratitude to the following persons who have made the completion
of this thesis possible: our supervisor, Deputy Chief physician,
Xiaofang Dong, for the vital guidance and support; and the
patient, for his understanding and willingness for publication.

References

[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin
2014;64:9–29.
[2] Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic
cancer patients: San Francisco Bay area, 1995–1999. Am J Epidemiol
2011;174:1373–81.
[3] Geer RJ, Brennan MF. Prognostic indicators for survival after resection
of pancreatic adenocarcinoma. Am J Surg 1995;165:68–72.
[4] Greto D, Scoccianti S, Compagnucci A, et al. Gamma knife radiosurgery
in the management of single and multiple brain metastases. Clin Neurol
Neurosurg 2016;141:43–7.
[5] Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic
cancer. World J Gastroenterol 2014;20:15110–8.
[6] Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and
deaths to 2030: the unexpected burden of thyroid, liver, and pancreas
cancers in the United States. Cancer Res 2014;74:2913–21.
[7] DiCarlo V, Balzano G, Zerbi A, et al. Pancreatic cancer resection in
elderly patients. Br J Surg 1998;85:607–10.
[8] Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection for
malignancy is safe and effective for the elderly. Ann Surg 1995;222:
426–34.
[9] Spencer MP, Sarr MG, Nagorney DM. Radical pancreatectomy for
pancreatic cancer in the elderly. Is it safe and justified? Ann Surg
1990;212:140–3.
[10] Bathe OF, Levi D, Caldera H, et al. Radical resection of periampullary
tumors in the elderly: evaluation of long-term results. World J Surg
2000;24:353–8.
[11] Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1
Methafur-0.4M 5-chloro-2,4-dihydroxypridine-1M potassium oxo-
nate (S-1) against human colon carcinoma orthotopically implanted into
male rats. Cancer Res 1996;56:2602–6.
[12] Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1
versus gemcitabine for resected pancreatic cancer: a phase 3, open-label,
randomised, non-inferiority trial (JASPAC 01). Lancet 2016;388:
248–57.
[13] Imaoka H, Tou K, Tanaka M, et al. Clinical outcome of elderly patients
with resectable pancreatic cancer treated with gemcitabine plus S-1, S-
alone, or gemcitabine alone: Subgroup analysis of a randomised phase
III trial, GEST study. Eur J Cancer 2016;54:96–103.
[14] Chao ST, Barnett GH, Vogelbaum MA, et al. Salvage stereotactic
radiosurgery effectively treats recurrences from whole-brain radiation
therapy. Cancer 2008;113:2198–204.
[15] Morizane C, Okusaka T, Ito Y, et al. Chemoradiotherapy for locally
advanced pancreatic carcinoma in elderly patients. Oncology 2005;68:
412–7.